Prescient Therapeutics Ltd has released a press release.
PTX-200 AML expansion after another complete response
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- March 2022 Quarterly Update and Appendix 4C
- Recruitment Open for Expansion Cohort of Phase 1B Study
- December 2021 Quarterly Update and Appendix 4C
- September 2021 Quarterly Activities and Appendix 4C
- Investor Presentation - October 2021
Later from Prescient Therapeutics
- PTX unveils new clinic-ready CAR-T enhancement platform
- PTX CellPryme-M presentation
- Key OmniCAR Patent Granted in US
- US FDA Grants Orphan Drug Designation to PTX-100 for PTCL
- June 2022 Quarterly Update and Appendix 4C
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics